JP2011503233A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011503233A5 JP2011503233A5 JP2010535014A JP2010535014A JP2011503233A5 JP 2011503233 A5 JP2011503233 A5 JP 2011503233A5 JP 2010535014 A JP2010535014 A JP 2010535014A JP 2010535014 A JP2010535014 A JP 2010535014A JP 2011503233 A5 JP2011503233 A5 JP 2011503233A5
- Authority
- JP
- Japan
- Prior art keywords
- yloxy
- pyridin
- diazepan
- methanone
- tetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- -1 cyclocyclobutyl Chemical group 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 8
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 4
- 206010041349 Somnolence Diseases 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 3
- 208000032140 Sleepiness Diseases 0.000 claims 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 230000006735 deficit Effects 0.000 claims 3
- 206010027175 memory impairment Diseases 0.000 claims 3
- 239000002207 metabolite Substances 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000019116 sleep disease Diseases 0.000 claims 3
- QVUOERZYMAHRRW-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(oxan-4-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2CCOCC2)N=CC=1C(=O)N(CC1)CCCN1C1CCC1 QVUOERZYMAHRRW-UHFFFAOYSA-N 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000001573 Cataplexy Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 206010016256 fatigue Diseases 0.000 claims 2
- 229960001340 histamine Drugs 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- VXAJSHFQQHNGQX-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-(6-cyclobutyloxypyridin-3-yl)methanone Chemical compound C=1C=C(OC2CCC2)N=CC=1C(=O)N(CC1)CCCN1C1CCC1 VXAJSHFQQHNGQX-UHFFFAOYSA-N 0.000 claims 1
- YNZIFJAHDHVCJE-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-(6-cyclohexyloxypyridin-3-yl)methanone Chemical compound C=1C=C(OC2CCCCC2)N=CC=1C(=O)N(CC1)CCCN1C1CCC1 YNZIFJAHDHVCJE-UHFFFAOYSA-N 0.000 claims 1
- ATMRCNUBMGDAJB-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-(6-cyclopentyloxypyridin-3-yl)methanone Chemical compound C=1C=C(OC2CCCC2)N=CC=1C(=O)N(CC1)CCCN1C1CCC1 ATMRCNUBMGDAJB-UHFFFAOYSA-N 0.000 claims 1
- JTJVOKQSNSXDSQ-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[5-(oxan-4-yloxy)pyridin-2-yl]methanone Chemical compound C=1C=C(OC2CCOCC2)C=NC=1C(=O)N(CC1)CCCN1C1CCC1 JTJVOKQSNSXDSQ-UHFFFAOYSA-N 0.000 claims 1
- WERIDDXCKXMLPN-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(1-ethylazepan-3-yl)oxypyridin-3-yl]methanone Chemical compound C1N(CC)CCCCC1OC1=CC=C(C(=O)N2CCN(CCC2)C2CCC2)C=N1 WERIDDXCKXMLPN-UHFFFAOYSA-N 0.000 claims 1
- UWCKCKPVQKWRLE-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(1-methylpiperidin-4-yl)oxypyridin-3-yl]methanone Chemical compound C1CN(C)CCC1OC1=CC=C(C(=O)N2CCN(CCC2)C2CCC2)C=N1 UWCKCKPVQKWRLE-UHFFFAOYSA-N 0.000 claims 1
- QIIMXKWOAINTGQ-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(1-methylpyrrolidin-3-yl)oxypyridin-3-yl]methanone Chemical compound C1N(C)CCC1OC1=CC=C(C(=O)N2CCN(CCC2)C2CCC2)C=N1 QIIMXKWOAINTGQ-UHFFFAOYSA-N 0.000 claims 1
- CIZGYGDRXHSNNY-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(1-propan-2-ylazepan-4-yl)oxypyridin-3-yl]methanone Chemical compound C1CN(C(C)C)CCCC1OC1=CC=C(C(=O)N2CCN(CCC2)C2CCC2)C=N1 CIZGYGDRXHSNNY-UHFFFAOYSA-N 0.000 claims 1
- OBURCTXWJHSPOX-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(cyclobutylmethoxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OCC2CCC2)N=CC=1C(=O)N(CC1)CCCN1C1CCC1 OBURCTXWJHSPOX-UHFFFAOYSA-N 0.000 claims 1
- VEXRDBRLGWUOJS-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(cyclopropylmethoxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OCC2CC2)N=CC=1C(=O)N(CC1)CCCN1C1CCC1 VEXRDBRLGWUOJS-UHFFFAOYSA-N 0.000 claims 1
- OXXUXAYRUZNWAN-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(oxan-4-yloxy)pyridin-2-yl]methanone Chemical compound C=1C=CC(OC2CCOCC2)=NC=1C(=O)N(CC1)CCCN1C1CCC1 OXXUXAYRUZNWAN-UHFFFAOYSA-N 0.000 claims 1
- NUYACTQCGLVCMC-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(oxepan-3-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2COCCCC2)N=CC=1C(=O)N(CC1)CCCN1C1CCC1 NUYACTQCGLVCMC-UHFFFAOYSA-N 0.000 claims 1
- LRPQZEPPDZMKDA-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(oxepan-4-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2CCOCCC2)N=CC=1C(=O)N(CC1)CCCN1C1CCC1 LRPQZEPPDZMKDA-UHFFFAOYSA-N 0.000 claims 1
- BFJLVORPAXGFKY-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(oxolan-3-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2COCC2)N=CC=1C(=O)N(CC1)CCCN1C1CCC1 BFJLVORPAXGFKY-UHFFFAOYSA-N 0.000 claims 1
- YWTLQMXBLFRANM-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(thian-4-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2CCSCC2)N=CC=1C(=O)N(CC1)CCCN1C1CCC1 YWTLQMXBLFRANM-UHFFFAOYSA-N 0.000 claims 1
- CPBJQSTWGOQQPN-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(thiepan-3-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2CSCCCC2)N=CC=1C(=O)N(CC1)CCCN1C1CCC1 CPBJQSTWGOQQPN-UHFFFAOYSA-N 0.000 claims 1
- XAEOEVMPYKYFCO-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(thiepan-4-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2CCSCCC2)N=CC=1C(=O)N(CC1)CCCN1C1CCC1 XAEOEVMPYKYFCO-UHFFFAOYSA-N 0.000 claims 1
- IDOPSVITNKOECG-UHFFFAOYSA-N (4-cyclobutyl-1,4-diazepan-1-yl)-[6-(thiolan-3-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2CSCC2)N=CC=1C(=O)N(CC1)CCCN1C1CCC1 IDOPSVITNKOECG-UHFFFAOYSA-N 0.000 claims 1
- MGCIMRQKRGCWIW-UHFFFAOYSA-N (4-cyclobutylpiperazin-1-yl)-[6-(oxan-4-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2CCOCC2)N=CC=1C(=O)N(CC1)CCN1C1CCC1 MGCIMRQKRGCWIW-UHFFFAOYSA-N 0.000 claims 1
- ZAMBPCHSYIEQEW-UHFFFAOYSA-N (4-cyclopentyl-1,4-diazepan-1-yl)-[6-(oxan-4-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2CCOCC2)N=CC=1C(=O)N(CC1)CCCN1C1CCCC1 ZAMBPCHSYIEQEW-UHFFFAOYSA-N 0.000 claims 1
- HIJUMTVHMNNALA-UHFFFAOYSA-N (4-cyclopentylpiperazin-1-yl)-[6-(oxan-4-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2CCOCC2)N=CC=1C(=O)N(CC1)CCN1C1CCCC1 HIJUMTVHMNNALA-UHFFFAOYSA-N 0.000 claims 1
- GDEYUSKKFOOEFV-UHFFFAOYSA-N (4-cyclopropyl-1,4-diazepan-1-yl)-[6-(oxan-4-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2CCOCC2)N=CC=1C(=O)N(CC1)CCCN1C1CC1 GDEYUSKKFOOEFV-UHFFFAOYSA-N 0.000 claims 1
- VRDXIGWWUIWIRM-UHFFFAOYSA-N (4-cyclopropyl-1,4-diazepan-1-yl)-[6-(oxolan-3-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2COCC2)N=CC=1C(=O)N(CC1)CCCN1C1CC1 VRDXIGWWUIWIRM-UHFFFAOYSA-N 0.000 claims 1
- LBRUZEHUUYGSJN-UHFFFAOYSA-N (4-cyclopropylpiperazin-1-yl)-[6-(oxan-3-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2COCCC2)N=CC=1C(=O)N(CC1)CCN1C1CC1 LBRUZEHUUYGSJN-UHFFFAOYSA-N 0.000 claims 1
- XOUOBAGFBFSLMB-UHFFFAOYSA-N (4-cyclopropylpiperazin-1-yl)-[6-(oxan-4-yloxy)pyridin-3-yl]methanone Chemical compound C=1C=C(OC2CCOCC2)N=CC=1C(=O)N(CC1)CCN1C1CC1 XOUOBAGFBFSLMB-UHFFFAOYSA-N 0.000 claims 1
- GQSAFMNDDDSCJD-UHFFFAOYSA-N 1-[3-[5-(4-cyclobutyl-1,4-diazepane-1-carbonyl)pyridin-2-yl]oxypyrrolidin-1-yl]ethanone Chemical compound C1N(C(=O)C)CCC1OC1=CC=C(C(=O)N2CCN(CCC2)C2CCC2)C=N1 GQSAFMNDDDSCJD-UHFFFAOYSA-N 0.000 claims 1
- CYUFBNIXXRIJMO-UHFFFAOYSA-N 1-[4-[5-(4-cyclobutyl-1,4-diazepane-1-carbonyl)pyridin-2-yl]oxyazepan-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCCC1OC1=CC=C(C(=O)N2CCN(CCC2)C2CCC2)C=N1 CYUFBNIXXRIJMO-UHFFFAOYSA-N 0.000 claims 1
- WRMDPNFCGVUCEJ-UHFFFAOYSA-N 1-[4-[5-(4-cyclobutyl-1,4-diazepane-1-carbonyl)pyridin-2-yl]oxypiperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1OC1=CC=C(C(=O)N2CCN(CCC2)C2CCC2)C=N1 WRMDPNFCGVUCEJ-UHFFFAOYSA-N 0.000 claims 1
- ZWEWUVQWWYKCEY-UHFFFAOYSA-N 3-cyclohexyloxy-6-(4-cyclopropyl-1,4-diazepane-1-carbonyl)pyridine-2-carbonitrile Chemical compound C=1C=C(OC2CCCCC2)C(C#N)=NC=1C(=O)N(CC1)CCCN1C1CC1 ZWEWUVQWWYKCEY-UHFFFAOYSA-N 0.000 claims 1
- HWIBZEXREFGUOK-UHFFFAOYSA-N 3-cyclopentyloxy-6-(4-cyclopropyl-1,4-diazepane-1-carbonyl)pyridine-2-carbonitrile Chemical compound C=1C=C(OC2CCCC2)C(C#N)=NC=1C(=O)N(CC1)CCCN1C1CC1 HWIBZEXREFGUOK-UHFFFAOYSA-N 0.000 claims 1
- NVXAPLQKZORNMX-UHFFFAOYSA-N 6-(4-cyclopropyl-1,4-diazepane-1-carbonyl)-3-(oxolan-3-yloxy)pyridine-2-carbonitrile Chemical compound C=1C=C(OC2COCC2)C(C#N)=NC=1C(=O)N(CC1)CCCN1C1CC1 NVXAPLQKZORNMX-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000017164 Chronobiology disease Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- YTYZYBQMJSYXCS-UHFFFAOYSA-N [6-(oxan-4-yloxy)pyridin-3-yl]-(4-propan-2-yl-1,4-diazepan-1-yl)methanone Chemical compound C1CN(C(C)C)CCCN1C(=O)C(C=N1)=CC=C1OC1CCOCC1 YTYZYBQMJSYXCS-UHFFFAOYSA-N 0.000 claims 1
- QVCDNGPZHDYLTF-UHFFFAOYSA-N [6-(oxan-4-yloxy)pyridin-3-yl]-(4-propan-2-ylpiperazin-1-yl)methanone Chemical compound C1CN(C(C)C)CCN1C(=O)C(C=N1)=CC=C1OC1CCOCC1 QVCDNGPZHDYLTF-UHFFFAOYSA-N 0.000 claims 1
- AOAATJGNDYOJLI-UHFFFAOYSA-N [6-(oxolan-3-yloxy)pyridin-3-yl]-(4-propan-2-yl-1,4-diazepan-1-yl)methanone Chemical compound C1CN(C(C)C)CCCN1C(=O)C(C=N1)=CC=C1OC1COCC1 AOAATJGNDYOJLI-UHFFFAOYSA-N 0.000 claims 1
- QFMMEHWYAXVVKG-UHFFFAOYSA-N [6-(oxolan-3-yloxy)pyridin-3-yl]-(4-propan-2-ylpiperazin-1-yl)methanone Chemical compound C1CN(C(C)C)CCN1C(=O)C(C=N1)=CC=C1OC1COCC1 QFMMEHWYAXVVKG-UHFFFAOYSA-N 0.000 claims 1
- JOQCUMLLZBXYRU-UHFFFAOYSA-N [6-[(3-methyloxetan-3-yl)methoxy]pyridin-3-yl]-(4-propan-2-yl-1,4-diazepan-1-yl)methanone Chemical compound C1CN(C(C)C)CCCN1C(=O)C(C=N1)=CC=C1OCC1(C)COC1 JOQCUMLLZBXYRU-UHFFFAOYSA-N 0.000 claims 1
- PSQBHHXUGLRPQZ-UHFFFAOYSA-N [6-[(3-methyloxetan-3-yl)methoxy]pyridin-3-yl]-(4-propan-2-ylpiperazin-1-yl)methanone Chemical compound C1CN(C(C)C)CCN1C(=O)C(C=N1)=CC=C1OCC1(C)COC1 PSQBHHXUGLRPQZ-UHFFFAOYSA-N 0.000 claims 1
- 230000007000 age related cognitive decline Effects 0.000 claims 1
- 125000003725 azepanyl group Chemical group 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000002920 convulsive effect Effects 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000013632 homeostatic process Effects 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000009245 menopause Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 201000003152 motion sickness Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000003551 oxepanyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000001583 thiepanyl group Chemical group 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 0 C*1(CCN(*)CC1)C(C1=CC=C(*)**1)=O Chemical compound C*1(CCN(*)CC1)C(C1=CC=C(*)**1)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98924607P | 2007-11-20 | 2007-11-20 | |
| US60/989,246 | 2007-11-20 | ||
| PCT/US2008/083764 WO2009067401A1 (en) | 2007-11-20 | 2008-11-17 | Cycloalkyloxy-and hetξrocycloalky- loxypyridine compounds as modulators of the histamine h3 receptor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011503233A JP2011503233A (ja) | 2011-01-27 |
| JP2011503233A5 true JP2011503233A5 (cg-RX-API-DMAC7.html) | 2012-01-05 |
| JP5498390B2 JP5498390B2 (ja) | 2014-05-21 |
Family
ID=40297867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010535014A Expired - Fee Related JP5498390B2 (ja) | 2007-11-20 | 2008-11-17 | ヒスタミンｈ３受容体のモジュレーターとしてのシクロアルキルオキシ−及びヘテロシクロアルキルオキシピリジン化合物 |
Country Status (22)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0324159D0 (en) | 2003-10-15 | 2003-11-19 | Glaxo Group Ltd | Novel compounds |
| US8288389B2 (en) * | 2007-09-06 | 2012-10-16 | Glaxo Group Limited | Piperazine derivative having affinity for the histamine H3 receptor |
| US20090318380A1 (en) | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
| BRPI0913057A2 (pt) * | 2008-05-08 | 2015-10-13 | Evotec Ag | azetidinas e ciclobutanos como antagonistas de receptor de histamina h3 |
| PL3216784T3 (pl) * | 2009-03-18 | 2019-07-31 | Janssen Pharmaceutica Nv | Sposób wytwarzania modulatorów receptorów histaminowych H3 |
| CN102638979A (zh) * | 2009-09-21 | 2012-08-15 | 范德比尔特大学 | 作为mGluR5 正变构调节剂的邻苄基烟酰胺 |
| US20140142070A1 (en) | 2011-07-07 | 2014-05-22 | Janssen R&D Ireland | Darunavir combination formulations |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE817911C (de) | 1947-12-16 | 1951-10-22 | Chem Fab Tempelhof Preuss & Te | Verfahren zur Darstellung von in 6-Stellung basisch substituierten Pyridin-3-carbonsaeureamiden |
| BE726551A (cg-RX-API-DMAC7.html) | 1968-01-22 | 1969-06-16 | ||
| ES436109A1 (es) | 1974-04-04 | 1977-01-01 | Christiaens Sa A | Procedimiento para la preparacion de nuevos derivados de pi-ridina. |
| EP0089765A3 (en) | 1982-03-17 | 1984-05-23 | Smith Kline & French Laboratories Limited | Pyridine derivatives |
| GB8311443D0 (en) | 1983-04-27 | 1983-06-02 | Smith Kline French Lab | Chemical compounds |
| GB8320505D0 (en) | 1983-07-29 | 1983-09-01 | Smith Kline French Lab | Chemical compounds |
| GB8332091D0 (en) | 1983-12-01 | 1984-01-11 | Smith Kline French Lab | Chemical compounds |
| JPS61149119A (ja) | 1984-12-22 | 1986-07-07 | 旭光学工業株式会社 | 検眼用試験枠 |
| US4792547A (en) | 1985-12-26 | 1988-12-20 | Hokuriku Pharmaceutical Co., Ltd. | Pyrazine-2-carboxamide derivatives useful in treating allergic disease |
| JPH0637595B2 (ja) | 1986-08-06 | 1994-05-18 | 日本ペイント株式会社 | 陰極電着塗料組成物 |
| GB9025828D0 (en) | 1990-11-28 | 1991-01-09 | Shell Int Research | Herbicidal carboxamide derivatives |
| JP3354271B2 (ja) | 1993-02-25 | 2002-12-09 | 三共株式会社 | ピリジルオキシアミド誘導体 |
| EP0761654B1 (en) | 1995-08-24 | 2003-06-18 | Basf Aktiengesellschaft | Isoxazole- and isothiazole-5-carboxamide derivatives, their preparation and their use as herbicides |
| WO1997024329A1 (en) | 1995-12-28 | 1997-07-10 | Kureha Kagaku Kogyo Kabushiki Kaisha | Process for producing pyridinecarboxamides or thiocarboxamides |
| TNSN97092A1 (ar) | 1996-09-18 | 1999-12-31 | Agouron Pharma | مثبطات انزيم بروتيني فلزي وتركيبات صيدلانية تحتوي على تلك المثبتطات واستخدامها الصيدلاني وطرق ومركبات وسيطة مفيدة لتحضير التركيبات المذكورة. |
| US6967196B1 (en) | 1999-02-26 | 2005-11-22 | Bristol-Myers Squibb Company | Sulfonamide compounds and uses thereof |
| MXPA01011905A (es) | 1999-05-21 | 2004-03-19 | Biovitrum Ab | Compuestos novedosos, su uso y preparacion. |
| US6399607B1 (en) | 1999-07-02 | 2002-06-04 | Research Foundation-State University Of New York | Aminomethylene amide analogs of pyrazinamide with intracellular antimycobacterial activity against pyrazinamide-resistant mycobacteria combined with a rifamycin |
| DE10023492A1 (de) | 2000-05-09 | 2001-11-22 | Schering Ag | Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel |
| US6645990B2 (en) | 2000-08-15 | 2003-11-11 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| JP2002322163A (ja) | 2001-04-20 | 2002-11-08 | Sumitomo Pharmaceut Co Ltd | ピペラジン誘導体 |
| WO2002100399A1 (en) * | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| EP1396487B1 (en) | 2001-06-15 | 2008-12-10 | Astellas Pharma Inc. | Phenylpyridine carbonyl piperazine derivative |
| US7208497B2 (en) | 2001-07-02 | 2007-04-24 | Novo Nordisk A/S | Substituted piperazines and diazepanes |
| EP1421071B1 (en) | 2001-07-02 | 2009-11-18 | High Point Pharmaceuticals, LLC | Substituted piperazine and diazepane derivaives as histamine h3 receptor modulators |
| AU2002363176B2 (en) | 2001-11-01 | 2008-09-25 | Janssen Pharmaceutica N.V. | Heteroaryl amines as glycogen synthase kinase 3Beta inhibitors (GSK3 inhibitors) |
| CA2463821A1 (en) | 2001-11-01 | 2003-05-08 | Janssen Pharmaceutica N.V. | Amide derivatives as glycogen synthase kinase 3-beta inhibitors |
| AU2003203148A1 (en) | 2002-02-05 | 2003-09-02 | High Point Pharmaceuticals, Llc | Novel aryl- and heteroarylpiperazines |
| GB0206219D0 (en) | 2002-03-15 | 2002-05-01 | Ferring Bv | Non-Peptide GnRH antagonists |
| AU2003226094A1 (en) | 2002-03-27 | 2003-10-13 | Smithkline Beecham Corporation | Compounds and methods |
| US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
| GB0209715D0 (en) | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| EP1388535A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylated arylcycloalkylamines and their use as pharmaceuticals |
| US20040110802A1 (en) | 2002-08-23 | 2004-06-10 | Atli Thorarensen | Antibacterial benzoic acid derivatives |
| GB0224084D0 (en) | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| AU2003274053A1 (en) | 2002-10-22 | 2004-05-13 | Glaxo Group Limited | Aryloxyalkylamine derivates as h3 receptor ligands |
| DE60330269D1 (de) | 2002-10-23 | 2010-01-07 | Janssen Pharmaceutica Nv | Piperazinyl- und diazapanylbenzamide und-benzothioamide |
| US7332508B2 (en) | 2002-12-18 | 2008-02-19 | Novo Nordisk A/S | Substituted homopiperidine, piperidine or pyrrolidine derivatives |
| AU2004257025B9 (en) | 2003-06-27 | 2010-05-27 | Msd K.K. | Heteroaryloxy nitrogenous saturated heterocyclic derivative |
| RU2006101452A (ru) | 2003-07-29 | 2006-06-27 | Ново Нордиск А/С (DK) | Пиридазинил-пиперазины и их применение в качестве лигандов h3 гистаминового рецептора |
| WO2005023247A1 (en) | 2003-09-03 | 2005-03-17 | Smithkline Beecham Corporation | Compounds and methods |
| GB0324159D0 (en) | 2003-10-15 | 2003-11-19 | Glaxo Group Ltd | Novel compounds |
| EP1761496A2 (en) | 2004-03-31 | 2007-03-14 | Janssen Pharmaceutica N.V. | Non-imidazole heterocyclic compounds as histamine h3-receptor ligands |
| AU2005231375A1 (en) | 2004-03-31 | 2005-10-20 | Janssen Pharmaceutica, N.V. | Non-imidazole heterocyclic compounds as histamine H3 receptor modulators |
| GB0514812D0 (en) * | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| EP1948607B1 (en) | 2005-09-16 | 2010-04-07 | Janssen Pharmaceutica, N.V. | Cyclopropyl amines as modulators of the histamine h3 receptor |
| CA2634250A1 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists |
| CA2634847A1 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Substituted aniline derivatives useful as histamine h3 antagonists |
| EP1994022A2 (en) | 2006-03-15 | 2008-11-26 | Wyeth a Corporation of the State of Delaware | N-substituted-azacyclylamines as histamine-3 antagonists |
| MX2008015365A (es) * | 2006-05-30 | 2008-12-16 | Janssen Pharmaceutica Nv | Compuestos de piridil amida sustituidos como moduladores del receptor h3 de la histamina. |
| EP2038269A1 (en) * | 2006-06-29 | 2009-03-25 | Janssen Pharmaceutica N.V. | Substituted benzamide modulators of the histamine h3 receptor |
| US20090131417A1 (en) * | 2007-11-20 | 2009-05-21 | Letavic Michael A | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor |
-
2008
- 2008-11-17 WO PCT/US2008/083764 patent/WO2009067401A1/en not_active Ceased
- 2008-11-17 CN CN200880117055A patent/CN101868454A/zh active Pending
- 2008-11-17 JP JP2010535014A patent/JP5498390B2/ja not_active Expired - Fee Related
- 2008-11-17 BR BRPI0820481-0A patent/BRPI0820481A2/pt not_active IP Right Cessation
- 2008-11-17 EA EA201070637A patent/EA018582B1/ru unknown
- 2008-11-17 MX MX2010005488A patent/MX2010005488A/es active IP Right Grant
- 2008-11-17 AU AU2008326561A patent/AU2008326561B2/en not_active Ceased
- 2008-11-17 CA CA2706328A patent/CA2706328C/en not_active Expired - Fee Related
- 2008-11-17 US US12/272,268 patent/US8883776B2/en not_active Expired - Fee Related
- 2008-11-17 NZ NZ584998A patent/NZ584998A/xx not_active IP Right Cessation
- 2008-11-17 UA UAA201007603A patent/UA103468C2/ru unknown
- 2008-11-17 KR KR1020107013252A patent/KR101546712B1/ko not_active Expired - Fee Related
- 2008-11-17 MY MYPI2010002288A patent/MY158253A/en unknown
- 2008-11-17 CN CN201610094782.9A patent/CN105712977B/zh not_active Expired - Fee Related
- 2008-11-17 EP EP08852442.6A patent/EP2222664B1/en not_active Not-in-force
- 2008-11-19 TW TW097144606A patent/TWI491604B/zh not_active IP Right Cessation
- 2008-11-20 AR ARP080105055A patent/AR069387A1/es not_active Application Discontinuation
- 2008-11-20 CL CL2008003465A patent/CL2008003465A1/es unknown
-
2010
- 2010-05-18 NI NI201000086A patent/NI201000086A/es unknown
- 2010-05-19 EC EC2010010190A patent/ECSP10010190A/es unknown
- 2010-05-20 CO CO10060285A patent/CO6210700A2/es active IP Right Grant
- 2010-06-18 ZA ZA2010/04334A patent/ZA201004334B/en unknown
- 2010-06-21 CR CR11529A patent/CR11529A/es not_active Application Discontinuation
-
2018
- 2018-02-14 AR ARP180100346A patent/AR110977A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011503233A5 (cg-RX-API-DMAC7.html) | ||
| HRP20192032T1 (hr) | Supstituirani 2-azabicikli i njihova upotreba kao modulatora receptora oreksina | |
| JP2008524262A5 (cg-RX-API-DMAC7.html) | ||
| CA2702482A1 (en) | Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | |
| JP2014526435A5 (cg-RX-API-DMAC7.html) | ||
| JP2009541216A5 (cg-RX-API-DMAC7.html) | ||
| JP2004517852A5 (cg-RX-API-DMAC7.html) | ||
| JP2013515026A (ja) | 置換されたベンズアミド誘導体 | |
| JP2011500694A5 (cg-RX-API-DMAC7.html) | ||
| JP2011500693A5 (cg-RX-API-DMAC7.html) | ||
| EP1901746B1 (en) | 4-fluoro-piperidine t-type calcium channel antagonists | |
| RU2010119528A (ru) | Замещенные n-фенилбипирролидинкарбоксамиды и их применение в лечебных целях | |
| JP2011500696A5 (cg-RX-API-DMAC7.html) | ||
| JP2008539195A (ja) | 新規のオキサジアゾール誘導体及びそれらの医学的使用 | |
| JP2011511001A5 (cg-RX-API-DMAC7.html) | ||
| CA2702933A1 (en) | Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof | |
| JP2011500697A5 (cg-RX-API-DMAC7.html) | ||
| JP2007504229A5 (cg-RX-API-DMAC7.html) | ||
| NO20083369L (no) | Anvendelse av substituert 2-imidazol av imidazolinderivater | |
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| KR20080103043A (ko) | 우울증 환자에게 있는 수면 장애의 치료를 위해 의도된 치료제를 수득하기 위한 아고멜라틴의 사용 | |
| JP2015521642A5 (cg-RX-API-DMAC7.html) | ||
| IL206914A0 (en) | Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands | |
| JP2015107945A (ja) | 神経新生に関する化合物及び医薬組成物 | |
| HRP20201405T1 (hr) | Derivat 5-etil-4-metil-pirazol-3-karboksamida, koji djeluje kao agonist taar-a |